Getting specific: targeting Fc receptors in myasthenia gravis

Affiliations

Comment

Jan D Lünemann. Nat Rev Neurol. 2021 Oct.

. 2021 Oct;17(10):597-598.

doi: 10.1038/s41582-021-00547-z.

¹ Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany. jan.luenemann@ukmuenster.de.

No abstract available

Comment on

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.

1. Toyka, K. V. et al. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N. Engl. J. Med. 296, 125–131 (1977). - DOI
1. Gilhus, N. E. et al. Myasthenia gravis. Nat. Rev. Dis. Primers 5, 30 (2019). - DOI
1. Dalakas, M. C. Immunotherapy in myasthenia gravis in the era of biologics. Nat. Rev Neurol. 15, 113–124 (2019). - DOI
1. Howard, J. F. Jr et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 20, 526–536 (2021). - DOI
1. argenx. argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis. argenx https://www.argenx.com/news/argenx-announces-fda-acceptance-bla-filing-e... (2021).